Do you struggle to keep on top of regulatory changes affecting the world of medicine and medical device clinical trials? Join thousands of subscribers who have discovered the convenience of our free monthly publication b...
-
ICON expands US early phase research capabilities
ICON plc today announced the expansion of its early phase capabilities with the opening of a new, state-of-the-art Clinical Research Unit (CRU) in San Antonio, Texas, as well as new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas.
-
ICON provides update on audit committee investigation and timing of fourth quarter and full year 2025 financial results
ICON plc today announced that the Audit Committee of the Board of Directors has completed its investigation into certain of the Company’s accounting practices and controls.
-
ICON and Advarra introduce new ‘research-ready,’ connected site network model
ICON plc and Advarra have entered a definitive partnership agreement to introduce a new ‘research-ready,’ connected site network model for clinical trials.
-
ICON plc provides update on timing of fourth quarter and full year 2025 earnings results and investigation into accounting practices
Investigation’s preliminary indications are that 2023 and 2024 revenue may have been overstated by less than 2% for each fiscal year
-
ICON’s Accellacare Site Network expands oncology research capabilities with new cancer institute partnership
ICON plc today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the opening of the Brian Moran Cancer Institute at Duly Health and Care in Illinois.
-
ICON 2025 global biotech survey
ICON plc today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market.
-
ICON survey reveals increasing clinical trial startup delays, underscoring need for human-centred site activation solutions
ICON plc today announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup.
-
ICON plc to present at the Jefferies London Healthcare Conference
ICON plc today announced that Mr. Barry Balfe, CEO of ICON plc and Mr. Nigel Clerkin, CFO of ICON plc, will present at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 am GMT.
-
ICON reports third quarter 2025 results
Quarter three revenue was $2,042.8 million representing an increase of 1.3% on quarter two 2025.
-
ICON plc schedules third quarter 2025 earnings conference call
ICON plc today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, October 22, 2025.
